Poseida Therapeutics Inc
NASDAQ:PSTX
Poseida Therapeutics Inc
NASDAQ:PSTX
Price:
2.97 USD
-6.01%
Market Closed
Updated:
May 22, 2024
Poseida Therapeutics Inc
Total Other Income
|
Poseida Therapeutics Inc
Total Other Income Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Other Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Poseida Therapeutics Inc
NASDAQ:PSTX
|
Total Other Income
$14.9m
|
CAGR 3-Years
177%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Other Income
-$3.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
-62%
|
CAGR 10-Years
-78%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Other Income
$158m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Other Income
$151m
|
CAGR 3-Years
126%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Other Income
-$55.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Other Income
-$31.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Poseida Therapeutics Inc's Total Other Income?
Total Other Income
14.9m
USD
14.9m
USD
Based on the financial report for Dec 31, 2023, Poseida Therapeutics Inc's Total Other Income amounts to 14.9m USD.
What is Poseida Therapeutics Inc's Total Other Income growth rate?
Total Other Income CAGR 3Y
177%
177%
Over the last year, the Total Other Income growth was 412%. The average annual Total Other Income growth rates for Poseida Therapeutics Inc have been 177% over the past three years .
You don't have any saved screeners yet
